Bessemer Group Inc Esperion Therapeutics, Inc. Transaction History
Bessemer Group Inc
- $61.6 Billion
- Q2 2025
A detailed history of Bessemer Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 127 shares of ESPR stock, worth $342. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127
Previous 127
-0.0%
Holding current value
$342
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ESPR
# of Institutions
181Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$37.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$31.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$27.9 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$26.9 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$18 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $180M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...